ScholarIQanswers from OpenAlex & ORCID
Toby M. Maher
ResearcherPublications, citations & collaboration network
Toby M. Maher is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Toby M. Maher have?
ScholarIQindexed works
Toby M. Maher has 942 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Toby M. Maher have?
ScholarIQcitation count
Toby M. Maher has 35,464 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Toby M. Maher?
ScholarIQh-index
Toby M. Maher has an h-index of 97 in OpenAlex.
What is the i10-index of Toby M. Maher?
ScholarIQi10-index
Toby M. Maher has an i10-index of 308 in OpenAlex.
What is the ORCID of Toby M. Maher?
ScholarIQorcid
The ORCID for Toby M. Maher is on the source record.
What is the OpenAlex record for Toby M. Maher?
ScholarIQopenalex
The OpenAlex for Toby M. Maher is on the source record.
What are the most-cited papers on Toby M. Maher?
ScholarIQmost cited works
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Paolo Spagnolo, Jonathan A. Kropski, Mark G. Jones, Joyce Lee, Giulio Rossi, Τheodoros Karampitsakos, Toby M. Maher, Argyrios Tzouvelekis, Christopher J. Ryerson
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
Gísli Jenkins, Juliet K. Simpson, Gauri Saini, Jane H Bentley, Anne‐Marie Russell, Rebecca Braybrooke, Philip L. Molyneaux, Tricia M. McKeever, Athol U. Wells, Aiden Flynn, Richard Hubbard, Diana Julie Leeming, Richard P. Marshall, M.A. Karsdal, Pauline T. Lukey, Toby M. Maher
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Benjamin Ng, Jinrui Dong, Giuseppe D’Agostino, Sivakumar Viswanathan, Anissa A. Widjaja, Wei‐Wen Lim, Nicole S. J. Ko, Jessie Tan, Sonia Chothani, Benjamin Huang, Chen Xie, Chee Jian Pua, Ann‐Marie Chacko, Nuno Guimarães‐Camboa, Sylvia Μ. Evans, Adam J. Byrne, Toby M. Maher, Jiurong Liang, Dianhua Jiang, Paul W. Noble, Sebastian Schäfer, Stuart A. Cook
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Toby M. Maher, Veronica A Tudor, Peter Saunders, Michael Gibbons, Sophie Fletcher, Christopher P. Denton, Rachel K. Hoyles, Helen Parfrey, Elisabetta Renzoni, Maria Kokosi, Athol U. Wells, Deborah Ashby, Mátyás Szigeti, Philip L. Molyneaux, Mohammed Akil, Daphne Babalis, Nazia Chaudhuri, Felix Chua, Arnab Data, Dhananjay Desai, Shrish Dubey, Natalie Dwyer, Marcus Flather, Richard Fordham, Carlota Grossi Sampedro, Frances Hall, Ira Jakupovic, Gregory J. Keir, Bipen D. Patel, Henry Penn, Arvind Rajasekaran, Lisa Spencer, Vicky Tsipouri, Zhe Wu, Georgio Xydopoulos, Fernando Zanghelini
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Paul F. Mercer, Hannah V. Woodcock, Jessica Eley, Manuela Platé, Michal Sulikowski, Pascal F. Durrenberger, Linda A. Franklin, Carmel B. Nanthakumar, Yim Man, Federica Genovese, Robin J. McAnulty, Shuying Yang, Toby M. Maher, Andrew G. Nicholson, Andy Blanchard, Richard P. Marshall, Pauline T. Lukey, Rachel C. Chambers